<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 02 May 2021 10:23:51 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>庆祝创号一周年，五一福利大放送！！！</title><link>https://mp.weixin.qq.com/s/C7B_pYMjBvt-1G3RJzioQQ</link><description></description><content:encoded><![CDATA[庆祝创号一周年，五一福利大放送！！！]]></content:encoded><pubDate>Sun, 02 May 2021 07:41:49 +0800</pubDate></item><item><title>个性化新抗原肿瘤疫苗的研究进展和挑战</title><link>https://mp.weixin.qq.com/s/HTF1G0v0Xal2NCVfzhazbg</link><description></description><content:encoded><![CDATA[个性化新抗原肿瘤疫苗的研究进展和挑战]]></content:encoded><pubDate>Sat, 01 May 2021 18:57:12 +0800</pubDate></item><item><title>FDA对3款PD-(L)1的6项加速批准“再审”</title><link>https://mp.weixin.qq.com/s/zuD2jSYlhhCzopWd1nLUfA</link><description></description><content:encoded><![CDATA[FDA对3款PD-(L)1的6项加速批准“再审”]]></content:encoded><pubDate>Fri, 30 Apr 2021 19:32:44 +0800</pubDate></item><item><title>Her2之后，正在内卷的Claudin 18.2！</title><link>https://mp.weixin.qq.com/s/-E4RTiPPZmLIixFCuYMEag</link><description></description><content:encoded><![CDATA[Her2之后，正在内卷的Claudin 18.2！]]></content:encoded><pubDate>Thu, 29 Apr 2021 19:30:05 +0800</pubDate></item><item><title>免疫检查点抑制剂获得性耐药机制的研究进展与挑战</title><link>https://mp.weixin.qq.com/s/SfYLBwLRhZ0l-PtOq-CGPg</link><description></description><content:encoded><![CDATA[免疫检查点抑制剂获得性耐药机制的研究进展与挑战]]></content:encoded><pubDate>Wed, 28 Apr 2021 19:58:00 +0800</pubDate></item><item><title>RSV疗法赛道竞争激烈，谁会胜出？</title><link>https://mp.weixin.qq.com/s/7MlI3-sLemmkTyToKzVl9A</link><description></description><content:encoded><![CDATA[RSV疗法赛道竞争激烈，谁会胜出？]]></content:encoded><pubDate>Tue, 27 Apr 2021 20:02:42 +0800</pubDate></item><item><title>集赞五一 脚踏祥云｜BiG携50+医药大咖喊你参会！</title><link>https://mp.weixin.qq.com/s/nocUCFuWpi7aXS9i4B1mzg</link><description></description><content:encoded><![CDATA[集赞五一 脚踏祥云｜BiG携50+医药大咖喊你参会！]]></content:encoded><pubDate>Tue, 27 Apr 2021 20:02:42 +0800</pubDate></item><item><title>AI制药中的先行者</title><link>https://mp.weixin.qq.com/s/R4BGdhQsq0EgSEJZfRRe3g</link><description></description><content:encoded><![CDATA[AI制药中的先行者]]></content:encoded><pubDate>Mon, 26 Apr 2021 19:54:01 +0800</pubDate></item><item><title>盘点2021上市的抗体新药-（3）loncastuximab tesirine-lpyl</title><link>https://mp.weixin.qq.com/s/Oo6fv89AqG6BhX3FETiUyQ</link><description></description><content:encoded><![CDATA[盘点2021上市的抗体新药-（3）loncastuximab tesirine-lpyl]]></content:encoded><pubDate>Sun, 25 Apr 2021 19:32:01 +0800</pubDate></item><item><title>新冠疫苗接种进展和竞争格局</title><link>https://mp.weixin.qq.com/s/use498pvusKZpJJK6pEwmw</link><description></description><content:encoded><![CDATA[新冠疫苗接种进展和竞争格局]]></content:encoded><pubDate>Sun, 25 Apr 2021 19:32:01 +0800</pubDate></item><item><title>盘点2021上市的抗体新药-（2）dostarlimab-gxly</title><link>https://mp.weixin.qq.com/s/iHeO1a8QhHXjgsUgDmw5jQ</link><description></description><content:encoded><![CDATA[盘点2021上市的抗体新药-（2）dostarlimab-gxly]]></content:encoded><pubDate>Sat, 24 Apr 2021 10:25:00 +0800</pubDate></item><item><title>自免明星靶点IL-17：从发现到靶向治疗</title><link>https://mp.weixin.qq.com/s/9l8o7MerYRyj_X5hXgk7XQ</link><description></description><content:encoded><![CDATA[自免明星靶点IL-17：从发现到靶向治疗]]></content:encoded><pubDate>Fri, 23 Apr 2021 19:47:59 +0800</pubDate></item><item><title>博际生物喊你入职啦！！！优质岗位等你来挑</title><link>https://mp.weixin.qq.com/s/uW8crplPtDvZdMhc7HpkAg</link><description></description><content:encoded><![CDATA[博际生物喊你入职啦！！！优质岗位等你来挑]]></content:encoded><pubDate>Fri, 23 Apr 2021 19:47:59 +0800</pubDate></item></channel></rss>